Edition:
United Kingdom

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.92USD
22 Jul 2019
Change (% chg)

$-0.33 (-14.67%)
Prev Close
$2.25
Open
$2.05
Day's High
$2.05
Day's Low
$1.92
Volume
19,263
Avg. Vol
407,025
52-wk High
$9.19
52-wk Low
$1.56

Latest Key Developments (Source: Significant Developments)

Akari Therapeutics Qtrly Loss Per Share $0.00
Wednesday, 29 May 2019 

May 29 (Reuters) - Akari Therapeutics PLC ::AKARI THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC - FURTHER CLINICAL DATA FROM BP AND AKC TRIALS ANTICIPATED IN 2019.AKARI THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF MARCH 30, 2019, COMPANY HAD CASH OF $6.1 MILLION, AS COMPARED TO CASH OF $5.4 MILLION AS OF DECEMBER 31, 2018.  Full Article

Akari Announces Q3 2018 Financial Results And Business Highlights
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Akari Therapeutics PLC ::AKARI ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC - TWO CLINICAL PROGRAMS EXPECTED TO REPORT INITIAL DATA IN Q1 2019.AKARI THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF SEPTEMBER 30, 2018, CO HAD CASH OF $10.1 MILLION, VERSUS $28.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT.AKARI THERAPEUTICS PLC - NEW DOSING REGIMEN AT 45 MG PER DAY IS EXPECTED TO BE USED IN PHASE III TRIALS.AKARI - PLANS TO COMMENCE TWO PHASE III PNH CLINICAL TRIALS WITH COVERSIN BEGINNING WITH CAPSTONE IN Q1 OF 2018.AKARI THERAPEUTICS PLC - ON TRACK TO PROGRESS INTO PHASE III CLINICAL TRIALS IN Q1 OF 2018.AKARI THERAPEUTICS PLC - SECOND PHASE III TRIAL, ASSET, IS PLANNED FOR H2 2018 & WILL INCLUDE SOLIRIS SWITCH PATIENTS.  Full Article

Akari Therapeutics says priced public offering of american depositary shares
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Akari Therapeutics Plc :Akari therapeutics announces pricing of public offering of american depositary shares.Akari therapeutics plc - priced public offering of 3.5 million american depositary shares, or adss, at $5.00 per ads​.  Full Article

Akari Therapeutics appoints David Horn Solomon as CEO
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Akari Therapeutics Plc ::Akari Therapeutics announces appointment of David Horn Solomon as CEO.Says Dr David Horn Solomon appointed CEO.Akari Therapeutics Plc - ‍david Horn Solomon will be appointed as company's new chief executive officer effective August 28​.  Full Article

Akari Therapeutics PLC files for mixed shelf of up to $100 mln
Friday, 18 Aug 2017 

Aug 18 (Reuters) - Akari Therapeutics PLC :Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing.  Full Article